Vimarsana
Biggest News Aggregation in the World

Page 28 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Vimarsana News

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on November 3, 2022 –NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bio...

Nasdaq Surges 150 Points; Snap Shares Plunge - Vimarsana News

Nasdaq Surges 150 Points; Snap Shares Plunge

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 500 points on Friday. The Dow traded up 1.95% to 30,924.25...

Dow Jumps 650 Points; Gold Rises Over 1% - Vimarsana News

Dow Jumps 650 Points; Gold Rises Over 1%

U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping around 650 points on Friday. The Dow traded up 2.16% to 30,988.75...

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate - Vimarsana News

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate - Vimarsana News

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...